Bronchogen

PeptideXpo buyer fit

Overview

Bronchogen is a Khavinson-class short-peptide bioregulator with the sequence Ala-Glu-Asp-Leu (AEDL), targeting respiratory-tissue regulatory pathways within the broader Khavinson bioregulator framework. The molecule was developed at the St. Petersburg Institute of Bioregulation and Gerontology as the respiratory-tissue member of the Khavinson short-peptide family, alongside Cortagen (cerebral cortex, AEDP), Pinealon (cognitive, EDR), Vesugen (vascular, KED), Cardiogen (cardiovascular), and others. The shared hypothesis is that short tissue-specific peptide fragments isolated from animal tissues act as endogenous bioregulators of cell-cycle and gene-expression programs in their target tissues; Bronchogen specifically is positioned in the Russian-school research literature as a regulatory peptide for bronchial epithelium and respiratory-tissue maintenance. PeptideXpo supplies Bronchogen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. CAS is not consistently registered across suppliers for the Khavinson bioregulator class, so identity is established via sequence verification by LC-MS/MS plus mass-spec confirmation of the AEDL tetrapeptide on the applicable batch COA when part of the agreed analytical scope, particularly important because the four members of the Khavinson tetrapeptide family (AEDG / AEDL / AEDP / KED) are close in mass and require explicit sequencing to disambiguate.

Who buys this, and why

Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

Not consistently registered; see batch COA

Sequence

AEDL

Appearance

White to off-white lyophilized powder

Purity (HPLC)

≥ 99.0%

Strength

20 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 30 minutes

MOQ

On request

Lead time

14–21 days

Storage

-20°C lyophilized; 2–8°C reconstituted, protect from light

Documentation available on request

• Certificate of Analysis (COA)
• Ratio-verification HPLC
• Mass-spec identity of each component
• Stability of the blend (matrix-specific)
• Bacterial endotoxin (LAL, USP <85>)
• Sterile-fill documentation (where applicable)
• SDS / MSDS
• Private-label / OEM specification sheet

Regulatory note

Khavinson bioregulator (Russian scientific lineage); CAS commonly not registered. Confirm AEDL sequence and identity per batch COA, disambiguation from sibling tetrapeptides (AEDG / AEDP / KED) in the family is essential since the masses are close.

Selected literature

1. Khavinson VKh, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A. Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. 2014;192(5):781-791.
2. Kuzubova NA, Lebedeva ES, Dvorakovskaya IV, Surkova EA, Platonova IS, Titova ON. Modulating effect of peptide therapy on the morphofunctional state of bronchial epithelium in rats with obstructive lung pathology. Bull Exp Biol Med. 2015;159(5):685-688.
3. Ashapkin VV, Linkova NS, Khavinson VKh, Vanyushin BF. Epigenetic mechanisms of peptidergic regulation of gene expression during aging of human cells. Biochemistry (Mosc). 2015;80(3):310-322.
4. Monaselidze JR, Khavinson VKh, Gorgoshidze MZ, Khachidze DG, Lomidze EM, Jokhadze TA, Lezhava TA. Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability. Bull Exp Biol Med. 2011;150(3):375-377.
5. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053.

Frequently asked questions